FDA accepts BLA for Alder's migraine therapy for infusion

FDA accepts BLA for Alder's migraine therapy for infusion

Source: 
BioCentury
snippet: 

Alder said FDA accepted a BLA for eptinezumab to prevent migraine. The company, which submitted the BLA on Feb. 21, said it expects to receive a PDUFA date within 74 days following the submission.